Asieris Pharmaceuticals

Asieris Pharmaceuticals company information, Employees & Contact Information

Asieris Pharmaceuticals, founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases. We strive to improve human health and help people live a more dignified life. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide. The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus. Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.

Company Details

Employees
60
Founded
-
Address
201 King Of Prussia Rd., Suite 650,united States
Phone
021-68585280-606
Email
dd****@****eris.cn
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
asieris.cn
Keywords
Beijing.
HQ
Radnor, Pennsylvania
Looking for a particular Asieris Pharmaceuticals employee's phone or email?

Asieris Pharmaceuticals Questions

News

Cyclin-dependent kinase inhibitors reported in Asieris patent - BioWorld MedTech

Cyclin-dependent kinase inhibitors reported in Asieris patent BioWorld MedTech

Asieris Pharmaceuticals describes new PRMT5 inhibitors for bladder cancer - BioWorld MedTech

Asieris Pharmaceuticals describes new PRMT5 inhibitors for bladder cancer BioWorld MedTech

Asieris positions repurposed urinary antibiotic in bladder cancer at ASCO GU - Clinical Trials Arena

Asieris positions repurposed urinary antibiotic in bladder cancer at ASCO GU Clinical Trials Arena

Asieris’ Cevira, the First Non-Vaccine Investigational Product for Cervical HSIL, Has Achieved Its Primary Endpoint - Femtech Insider

Asieris’ Cevira, the First Non-Vaccine Investigational Product for Cervical HSIL, Has Achieved Its Primary Endpoint Femtech Insider

Asieris Pharmaceuticals Announces the Appointment of Baohua Chen as Executive Vice President of Finance - MarketScreener

Asieris Pharmaceuticals Announces the Appointment of Baohua Chen as Executive Vice President of Finance MarketScreener

Asieris showcases Phase III win in treating precancerous cervical lesions - Clinical Trials Arena

Asieris showcases Phase III win in treating precancerous cervical lesions Clinical Trials Arena

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China - Notimérica

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China Notimérica

Asieris appoints Dr Badrinath Konety to scientific advisory board - BioSpectrum Asia

Asieris appoints Dr Badrinath Konety to scientific advisory board BioSpectrum Asia

Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting - Finansavisen

Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting Finansavisen

Asieris reports interim results from MIBC therapy trial - Clinical Trials Arena

Asieris reports interim results from MIBC therapy trial Clinical Trials Arena

Asieris’ drug-device combo positive in cervical cancer trial - BioWorld MedTech

Asieris’ drug-device combo positive in cervical cancer trial BioWorld MedTech

US FDA grants IND clearance for Asieris’ ulcerative colitis drug trial - Clinical Trials Arena

US FDA grants IND clearance for Asieris’ ulcerative colitis drug trial Clinical Trials Arena

Top Asieris Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant